Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

New type of drug shows promise for chronic lymphocytic leukemia

A new type of engineered drug candidate has shown promise in treating chronic lymphocytic leukemia in both test tube and early animal tests, a new study shows.

29 Jun 2007

Discovery of inherited gene mutation for leukemia

Researchers have discovered the first inherited gene mutation that increases a person's risk for chronic lymphocytic leukemia (CLL), one of the most common forms of the disease.

1 Jun 2007

Knocking out Mcl1 protein could aid leukemia treatment

An effective way to fight leukemia might be to knock out a specific protein that protects cancer cells from dying, a new study shows.

21 Apr 2007

Researchers induce cell death in leukemia

Researchers from the Virginia Commonwealth University Massey Cancer Center presented preclinical research at the American Association of Cancer Research's annual meeting suggesting the potential of a new combination treatment for chronic lymphocytic leukemia (CLL).

17 Apr 2007

CuraGen announces results with Belinostat and Velafermin

CuraGen Corporation has announced that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of severe oral mucositis, will be presented at the upcoming American Association for Cancer Research (AACR) 2007 Annual Meeting in Los Angeles, CA, April 14-18, 2007.

15 Apr 2007

Turning the immune system against cancer

Medicine can now prevent a host of diseases with a mere shot of vaccine. Polio and smallpox are almost non-existent, and mumps and chicken pox are rarely seen nowadays.

4 Aug 2006

Roswell Park research aids development of myeloma drug

Roswell Park Cancer Institute (RPCI) researchers played a leading role in clinical studies which led to U.S. Food and Drug Administration (FDA) approval of a new treatment for patients diagnosed with multiple myeloma - the second most common blood cancer.

11 Jul 2006

Scientists identify microRNAs that appear to play a role in the development of platelets

Scientists have identified a handful of microRNAs (miRNAs) that appear to play a significant role in the development of platelets - blood cells critical to the body's ability to form clots following an injury.

21 Mar 2006

New and unusual class of genes plays an important role in the development of chronic lymphocytic leukemia

The study found that the loss of two genes for producing small molecules known as microRNAs enables damaged cells to survive, rather than normally self-destructing before they become cancerous.

12 Sep 2005

Experts on chronic lymphocytic leukemia (CLL) review current scientific knowledge

When the most common adult leukemia in the United States was last reviewed by the New England Journal of Medicine (NEJM) in 1995, it was seen through the eyes of theories that dated back to the 1960s.

24 Feb 2005

FDA accepts Genmab's Investigational New Drug Application for active rheumatoid arthritis treatment

Genmab announced today the US Food and Drug Administration (FDA) accepted its Investigational New Drug Application (IND) to start a Phase I/II dose escalation trial for HuMax-CD20 to treat patients with active rheumatoid arthritis (RA) who have failed one treatment with one or more disease modifying anti-rheumatic drugs (DMARDs).

13 Dec 2004

Obesity could more than double an older woman's risk of acute myelogenous leukemia

A study from the University of Minnesota Cancer Center indicates that overweight and obesity could more than double an older woman's risk of acute myelogenous leukemia (AML), an often fatal cancer of the bone marrow and blood.

8 Nov 2004

Microchip to track genetic signature of cancer and normal tissue

MicroRNAs (miRNAs), tiny pieces of genetic material that can serve as stop signs for gene expression and protein synthesis, are thought to be important in the development of cancer.

23 Jun 2004

Results from study of Rituxan in rheumatoid arthritis show promise

Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.

16 Jun 2004